MIRA PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MIRA PHARMACEUTICALS, INC. | ||
| Date: April 1, 2024 | By: | /S/ Erez Aminov |
|---|---|---|
| Name: | Erez Aminov | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer) | ||
| By: | /S/ Michelle Yanez | |
| Name: | Michelle Yanez | |
| Title: | Chief Financial Officer | |
| (Principal Financial Officer) | ||
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Person | Capacity | Date |
|---|---|---|
| /s/ Erez Aminov | Chief Executive Officer and Chairman | April 1, 2024 |
| Erez Aminov | ||
| /s/ Michelle Yanez | Chief Financial Officer | April 1, 2024 |
| Michelle Yanez | ||
| /s/ Michael Jerman | Director | April 1, 2024 |
| Michael Jerman | ||
| /s/ Matthew Del Giudice | Director | April 1, 2024 |
| Matthew Del Giudice | ||
| /s/ Denil Shekhat | Director | April 1, 2024 |
| Denil Shekhat | ||
| /s/ Edward MacPherson | Director | April 1, 2024 |
| Edward MacPherson | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.